Crinetics reiterates preliminary Q4 2025 PALSONIFY net product revenue over $5.0M

Crinetics Pharmaceuticals, Inc.

2025-FY EPS reported -$4.95 revenue$7,696,000

Net product revenue from PALSONIFY (paltusotine) exceeds $5.0M for Q4 2025.
Audited FY2025 financials not yet available; estimates are preliminary and unaudited.
CEO Scott Struthers presents company update at J.P. Morgan Healthcare Conference on Jan 13, 2026.
Corporate slide presentation furnished as Exhibit 99.1.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.